Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis: Group of systemic vasculitis with a strong association with ANCA. The disorders are characterized by necrotizing inflammation of small and medium size vessels, with little or no immune-complex deposits in vessel walls.Vasculitis: Inflammation of any one of the blood vessels, including the ARTERIES; VEINS; and rest of the vasculature system in the body.Antibodies, Antineutrophil Cytoplasmic: Autoantibodies directed against cytoplasmic constituents of POLYMORPHONUCLEAR LEUKOCYTES and/or MONOCYTES. They are used as specific markers for GRANULOMATOSIS WITH POLYANGIITIS and other diseases, though their pathophysiological role is not clear. ANCA are routinely detected by indirect immunofluorescence with three different patterns: c-ANCA (cytoplasmic), p-ANCA (perinuclear), and atypical ANCA.Microscopic Polyangiitis: A primary systemic vasculitis of small- and some medium-sized vessels. It is characterized by a tropism for kidneys and lungs, positive association with anti-neutrophil cytoplasmic antibodies (ANCA), and a paucity of immunoglobulin deposits in vessel walls.Wegener Granulomatosis: A multisystemic disease of a complex genetic background. It is characterized by inflammation of the blood vessels (VASCULITIS) leading to damage in any number of organs. The common features include granulomatous inflammation of the RESPIRATORY TRACT and kidneys. Most patients have measurable autoantibodies (ANTINEUTROPHIL CYTOPLASMIC ANTIBODIES) against neutrophil proteinase-3 (WEGENER AUTOANTIGEN).Antibodies, Monoclonal, Murine-Derived: Antibodies obtained from a single clone of cells grown in mice or rats.Remission Induction: Therapeutic act or process that initiates a response to a complete or partial remission level.Peroxidase: A hemeprotein from leukocytes. Deficiency of this enzyme leads to a hereditary disorder coupled with disseminated moniliasis. It catalyzes the conversion of a donor and peroxide to an oxidized donor and water. EC 1.11.1.7.Churg-Strauss Syndrome: Widespread necrotizing angiitis with granulomas. Pulmonary involvement is frequent. Asthma or other respiratory infection may precede evidence of vasculitis. Eosinophilia and lung involvement differentiate this disease from POLYARTERITIS NODOSA.Immunosuppressive Agents: Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging.Recurrence: The return of a sign, symptom, or disease after a remission.Glomerulonephritis: Inflammation of the renal glomeruli (KIDNEY GLOMERULUS) that can be classified by the type of glomerular injuries including antibody deposition, complement activation, cellular proliferation, and glomerulosclerosis. These structural and functional abnormalities usually lead to HEMATURIA; PROTEINURIA; HYPERTENSION; and RENAL INSUFFICIENCY.Prednisolone: A glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states.Myeloblastin: A polymorphonuclear leukocyte-derived serine protease that degrades proteins such as ELASTIN; FIBRONECTIN; LAMININ; VITRONECTIN; and COLLAGEN. It is named for its ability to control myeloid cell growth and differentiation.Treatment Outcome: Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.

*  ChemoCentryx Announces Presentations of Positive Results from Phase II ANCA-Associated Vasculitis Trials ('CLEAR' and 'CLASSIC'...

About ANCA-Associated Vasculitis. Anti-neutrophil cytoplasmic auto-antibody (ANCA)-associated vasculitis, or AAV, is a type of ... in patients with anti-neutrophil cytoplasmic auto-antibody (ANCA) -associated vasculitis (AAV). Avacopan is a potent orally- ... is in Phase II development for the treatment of anti-neutrophil cytoplasmic auto- antibody associated vasculitis (AAV). ... By blocking the C5aR, avacopan is thought to reduce vasculitis by reducing neutrophil activation, accumulation, and adhesion, ...

*  Antineutrophil cytoplasmic antibody-associated vasculitides: is it time to split up the group? | Annals of the Rheumatic...

Anti-MPO and anti-PR3 antibodies can activate neutrophils in vitro. In vivo data are available for humans and mice on the ... Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitides are a heterogeneous group of diseases corresponding to ... Antineutrophil cytoplasmic antibody-associated vasculitides: is it time to split up the group? ... Antineutrophil cytoplasmic antibody-associated vasculitides: is it time to split up the group? ...

*  Search of: Recruiting, Not yet recruiting, Available Studies | 'Wegener Granulomatosis' - List Results - ClinicalTrials.gov

Low-dose Glucocorticoid Vasculitis Induction Study. *Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis ... Unique pregnancy characteristics among women with vasculitis.. 100. Female. 18 Years to 50 Years (Adult). NCT02593565. VCRC ... Identify genes that increase the risk of developing vasculitis. 1000. All. Child, Adult, Senior. NCT02967068. VCRC5511. ... Number of patients in complete remission (defined by a Birmingham Vasculitis Activity Score (BVAS) of 0 and a prednisone dose ≤ ...

*  A Phase IIa Study of Intravenous Rituximab in Pediatric Participants With Severe Granulomatosis With Polyangiitis (Wegener&apos...

Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis. Autoimmune Diseases. Immune System Diseases. Cerebral Small Vessel ... anti-CD4, anti-CD5, anti-CD3, and anti-CD11a) ... anti-CD20, anti-CD22, or anti-B-lymphocyte stimulator [BLys]/B- ... Previous treatment with an anti-alpha 4 integrin antibody or co-stimulation modulator ... Systemic Vasculitis. Granulomatosis with Polyangiitis. Vasculitis. Vascular Diseases. Cardiovascular Diseases. Lung Diseases, ...

*  Rituximab Vasculitis Maintenance Study - Tabular View - ClinicalTrials.gov

Rituximab is now established as an effective drug for anti-neutrophil cytoplasmic antibody (ANCA) vasculitis following major ... A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis ... versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a ... A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J ...

*  One-Time DNA Study for Vasculitis - Full Text View - ClinicalTrials.gov

Vasculitis. Systemic Vasculitis. Vasculitis, Central Nervous System. Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis ... Antineutrophil cytoplasmic antibody (ANCA) positive by enzyme immunoassay for either PR3- or MPO-ANCA ... Each type of vasculitis is a rare ('orphan') disease. However, taken together, vasculitis affects tens of thousands of ... The Vasculitis Clinical Research Consortium (VCRC) currently focuses on 6 specific types of vasculitis that were selected to ...

*  Belimumab in Remission of VASculitis - Full Text View - ClinicalTrials.gov

anti-proteinase 3. anti-neutrophil cytoplasmic antibody. anti-myeloperoxidase. Granulomatosis with polyangiitis. Vasculitis. ... Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis. Systemic Vasculitis. Autoimmune Diseases. Immune System Diseases. ... Tested positive for anti-proteinase 3 (anti-PR3) or anti-myeloperoxidase (anti-MPO) antibodies at any time prior to enrollment. ... Belimumab in Remission of VASculitis (BREVAS). The safety and scientific validity of this study is the responsibility of the ...

*  CHUSPAN PAN BP Treatment of Polyarteritis Nodosa and Microscopic Polyangiitis Without Poor-Prognosis Factors - Full Text View -...

Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis. Autoimmune Diseases. Immune System Diseases. Arteritis. Skin ... Systemic Vasculitis. Microscopic Polyangiitis. Polyarteritis Nodosa. Vasculitis. Vascular Diseases. Cardiovascular Diseases. ... Samson M, Puéchal X, Devilliers H, Ribi C, Cohen P, Bienvenu B, Terrier B, Pagnoux C, Mouthon L, Guillevin L; French Vasculitis ...

*  Alemtuzumab for ANCA Associated Refractory Vasculitis - Full Text View - ClinicalTrials.gov

Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis. Autoimmune Diseases. Immune System Diseases. Cerebral Small Vessel ... Treatment failure is defined as the failure to achieve a vasculitis response by six months or a vasculitis relapse between 6 ... Vasculitis. Systemic Vasculitis. Granulomatosis with Polyangiitis. Microscopic Polyangiitis. Vascular Diseases. Cardiovascular ... Alemtuzumab for ANCA Associated Refractory Vasculitis (ALEVIATE). The safety and scientific validity of this study is the ...

*  Mycophenolate Mofetil for Treatment of Relapses of Wegener's Disease or Microscopic Polyangiitis (MPA) - Full Text View -...

Vasculitis. Granulomatosis with Polyangiitis. Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis. Microscopic ... Systemic Vasculitis. Autoimmune Diseases. Immune System Diseases. Cerebral Small Vessel Diseases. Cerebrovascular Disorders. ... MedlinePlus related topics: Granulomatosis with Polyangiitis Vasculitis Drug Information available for: Cyclophosphamide ... Treatment of ANCA-associated vasculitis consists of two phases: remission induction with highly effective, but also relatively ...

*  Determining Disease Activity Biomarkers in Individuals With Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss) -...

Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis. Autoimmune Diseases. Immune System Diseases. Granuloma. ... Antineutrophil cytoplasmic antibodies (ANCA). Autoimmunity. 2005 Feb;38(1):93-103. Review. ... Systemic Vasculitis. Granulomatosis with Polyangiitis. Vasculitis. Vascular Diseases. Cardiovascular Diseases. Lung Diseases, ... Pathogenesis of pulmonary vasculitis. Semin Respir Crit Care Med. 2004 Oct;25(5):465-74. ...

*  Plasma Exchange and Glucocorticoids for Treatment of Anti-Neutrophil Cytoplasm Antibody (ANCA) - Associated Vasculitis - Full...

Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis. Autoimmune Diseases. Immune System Diseases. Cerebral Small Vessel ... Plasma Exchange and Glucocorticoid Dosing in the Treatment of Anti-neutrophil Cytoplasm Antibody Associated Vasculitis: an ... Plasma exchange and glucocorticoid dosing in the treatment of anti-neutrophil cytoplasm antibody associated vasculitis (PEXIVAS ... Plasma Exchange and Glucocorticoids for Treatment of Anti-Neutrophil Cytoplasm Antibody (ANCA) - Associated Vasculitis (PEXIVAS ...

*  Comparison Study of Two Rituximab Regimens in the Remission of ANCA Associated Vasculitis - Full Text View - ClinicalTrials.gov

Vasculitis. Systemic Vasculitis. Granulomatosis with Polyangiitis. Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis. ... anti-neutrophil cytoplasmic antibodies) at the time of diagnosis or relapse, and at remission. ... Number of patients with ANCA (Anti-Neutrophil Cytoplasmatic Antibodies) [ Time Frame: at 28 months ]. Number of patients with ... Comparison Study of Two Rituximab Regimens in the Remission of ANCA Associated Vasculitis (MAINRITSAN 2). The safety and ...

*  Mark Little : Profiles - Trinity Research : Trinity College DublinMark Little

Markers for work disability in anti-neutrophil cytoplasmic antibody-associated vasculitis., Rheumatology, 53, (5), 2014, p953-6 ... of anti-TNF-alpha antibodies in an experimental model of anti-neutrophil cytoplasm antibody-associated systemic vasculitis., ... Anti-Neutrophil Cytoplasmic Antibodies Stimulate Release of Neutrophil Microparticles, JOURNAL OF THE AMERICAN SOCIETY OF ... Experimental Autoimmune Vasculitis An Animal Model of Anti-neutrophil Cytoplasmic Autoantibody-Associated Systemic Vasculitis, ...

*  Anti-neutrophil cytoplasmic antibody - Wikipedia

Stegeman, CA (Nov 2005). "Predictive value of antineutrophil cytoplasmic antibodies in small-vessel vasculitis: is the glass ... Anti-neutrophil cytoplasmic antibodies (ANCAs) are a group of autoantibodies, mainly of the IgG type, against antigens in the ... images of pANCA and cANCA fluorescence images of ANCA Anti-Neutrophil Cytoplasmic Antibody at the US National Library of ... Jennette, JC; Xiao, H; Falk, RJ (May 2006). "Pathogenesis of vascular inflammation by anti-neutrophil cytoplasmic antibodies". ...

*  Anti-GPCR C5L2 antibody (ab77982) | Abcam

Rabbit polyclonal GPCR C5L2 antibody validated for WB, IHC and tested in Human. Referenced in 1 publication. Immunogen ... C5a and its receptors in human anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis.. Arthritis Res Ther 14:R140 ( ... Primary antibodies. Secondary antibodies. ELISA, Matched Antibody Pairs and Multiplex Immunoassays. Cell and tissue imaging ... Custom antibody development. We offer world-leading antibody development platforms based on a proprietary RabMAb® rabbit ...

*  US Patent # 8,234,099. Computer program for determining a nutritional diet product for a canine or feline animal - Patents...

... anti-neutrophil cytoplasmic antibody, marker for vasculitis; complement tests; leukocyte chemotaxis tests; urine protein/ ... and anti-leukocyte antibody tests (direct and indirect anti-neutrophil cytoplasmic antibody, antilymphocyte antibody, etc.). ... anti-platelet antibody, and anti-megakaryocyte antibody tests (see Test 3). Test 8: Diagnostic Test Panels for Vaccinal ... anti-platelet antibody tests (serum, bone marrow); anti-megakaryocyte antibody tests (IFA, elution); ...

*  Hyon Choi | Arthritis Research Canada

Clinical outcomes of treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis based on ANCA type. Ann ... and Rituximab on Body Composition During Induction Treatment of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. ... Myeloperoxidase-Antineutrophil Cytoplasmic Antibody (ANCA)-Positive and ANCA-Negative Patients With Granulomatosis With ... Lee T, Lu N, Felson DT, Choi HK, Dalal DS, Zhang Y, Dubreuil M. Use of non-steroidal anti-inflammatory drugs correlates with ...

*  Pulmonary haemorrhage complicating Wegener's granulomatosis and microscopic polyarteritis. - Semantic Scholar

In contrast with patients with antibasement membrane antibodies there was no correlation between pulmonary haemorrhage and ... Pulmonary haemorrhage is a cause of serious morbidity in patients with systemic vasculitis. ... The incidence and characteristics of pulmonary haemorrhage in a series of 89 patients with systemic vasculitis were analysed. ... Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis in Mexican Population: Clinical Phenotype, Autoantibody Profile and ...

*  Editorial issue 333

... levels and infection risk with rituximab induction for anti-neutrophil cytoplasmic antibody-associated vasculitis".. CME ... In Pediatric Kidney Transplant Recipients, Antibody Response Linked With Rejection. *More Paired Kidney Exchanges Could ... In Pediatric Kidney Transplant Recipients, Antibody Response Linked With Rejection. *More Paired Kidney Exchanges Could ... Alternate drug therapy lowers antibodies in kidney patients - may decrease the likelihood of organ rejection ...

*  Study Reveals Why Some Kidney Disease Patients Lose Ability to Repair Blood Vessels

Previous research has detailed how patients with an autoimmune disease produce antibodies that damage blood vessels in the ... Patients with an autoimmune kidney disorder called anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis produce ... how patients with an autoimmune disease called anti-neutrophil cytoplasmic antibody-associated vasculitis produce antibodies ... 50,000 patients around the world who have anti-neutrophil cytoplasmic antibody-associated vasculitis, plus those with other ...

*  Most recent papers with the keyword Collapsing glomerulopathy | Read by QxMD

Collapsing glomerulopathy in a case of anti-neutrophil cytoplasmic antibody associated vasculitis. ... till date there is no report of CG in association with the anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis ( ... com/read/27051140/collapsing-glomerulopathy-in-a-case-of-anti-neutrophil-cytoplasmic-antibody-associated-vasculitis ... A second renal biopsy showed dilation of glomerular capillary loops as a result of effective treatment with rapamycin and anti- ...

*  Most recent papers with the keyword Muscle weakness, pain | Read by QxMD

Anti-Neutrophil Cytoplasmic Antibody-associated Vasculitis (AAV) Restricted to the Limbs: A Case Report. ... www.readbyqxmd.com/read/29279515/anti-neutrophil-cytoplasmic-antibody-associated-vasculitis-aav-restricted-to-the-limbs-a-case- ... We detected elevated levels of inflammatory makers and PR3-anti-neutrophil cytoplasmic antibody (ANCA). Subsequently, the ... A subset of patients with CADM has a specific antibody known as anti-MDA5. These patients have a more aggressive course with ...

*  A Randomized, Double-Blind, Active-Controlled, Phase 3 Study to Evaluate the Safety and Efficacy of CCX168 (Avacopan) in...

... in Patients with Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis Treated Concomitantly with Rituximab or ... in Patients with Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis Treated Concomitantly with Rituximab or ...

*  After 40 Years, NIH-Supported Researchers Identify Possible New Treatment for Severe Vasculitis | WebWire

... anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis, a rare but devastating disease of blood... ... Investigators have made a major advance in treating people with a severe form of vasculitis, ... anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis, a rare but devastating disease of blood vessels. In a six- ... Patients with ANCA-associated vasculitis make antibodies that attack immune cells called neutrophils, causing inflammation in ...

(1/99) Predictors of treatment resistance and relapse in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis: comparison of two independent cohorts.

 (+info)

(2/99) Chimeric IgG4 PR3-ANCA induces selective inflammatory responses from neutrophils through engagement of Fcgamma receptors.

 (+info)

(3/99) CT60 and +49 polymorphisms of CTLA 4 are associated with ANCA-positive small vessel vasculitis.

 (+info)

(4/99) Increased incidence of cardiovascular events in patients with antineutrophil cytoplasmic antibody-associated vasculitides: a matched-pair cohort study.

 (+info)

(5/99) Small vessel vasculitis.

 (+info)

(6/99) Spontaneous resolution of delayed onset large subclavian artery pseudoaneurysm.

A 70-year-old woman with a history of end-stage renal disease secondary to anti-neutrophil cytoplasmic autoantibody-associated vasculitis had been receiving hemodialysis for 5 years. The patient underwent attempted right internal jugular vein cannulation for temporary hemodialysis catheter placement. Pulsating mass developed in the neck and angiography revealed a subclavian artery pseudoaneurysm 4 days later. The pseudoaneurysm disappeared spontaneously during the interval between the diagnosis and the planned surgical procedure. Such delayed onset and spontaneous resolution of subclavian artery pseudoaneurysm is uncommon. Close observation may be optimal if delayed onset of pseudoaneurysm occurs after small needle puncture with cessation of antiplatelet/anticoagulant administration.  (+info)

(7/99) Confirmation of the genetic association of CTLA4 and PTPN22 with ANCA-associated vasculitis.

 (+info)

(8/99) Prediction of ESRD in pauci-immune necrotizing glomerulonephritis: quantitative histomorphometric assessment and serum creatinine.

 (+info)



microscopic polyangiitis

  • The purpose of this study is to determine the efficacy and safety of a new drug, mycophenolate mofetil, for the treatment of relapses of ANCA-associated vasculitis (Wegener's granulomatosis or microscopic polyangiitis). (clinicaltrials.gov)
  • Granulomatosis with polyangiitis (Wegener's) (WG) and microscopic polyangiitis (MPA) are syndromes of primary systemic vasculitis associated with anti-neutrophil cytoplasm antibodies (ANCA). (clinicaltrials.gov)

Treatment

  • Treatment of ANCA-associated vasculitis consists of two phases: remission induction with highly effective, but also relatively toxic drugs, and, secondly, after remission is achieved, maintenance therapy with less toxic drugs. (clinicaltrials.gov)